{"gene":"PRKCH","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":1991,"finding":"PKC-L (PRKCH) binds phorbol esters and has kinase activity stimulated by phorbol esters, as demonstrated by introduction of the cDNA into COS cells.","method":"COS cell expression, phorbol ester binding assay, kinase activity assay","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct kinase activity and phorbol ester binding demonstrated in COS cells, single lab, two orthogonal methods (binding + kinase assay)","pmids":["1986216"],"is_preprint":false},{"year":1992,"finding":"Recombinant PKC-L(eta) expressed in insect cells via baculovirus binds phorbol ester similarly to PKC-gamma but shows distinctively different behavior toward conventional PKC substrates (histone, myelin basic protein, protamine), suggesting either incomplete activation by phorbol esters or different substrate specificity compared to group A PKC enzymes.","method":"Baculovirus/insect cell recombinant protein expression, phorbol ester binding assay, in vitro kinase assay with multiple substrates","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic reconstitution with multiple substrates and orthogonal binding assay, single lab","pmids":["1590767"],"is_preprint":false},{"year":1992,"finding":"PKC-L (PRKCH) is localized permanently and specifically in the cell nucleus, as shown by immunofluorescence staining and subcellular fractionation of multiple human cell lines including A431. Unlike classical PKC members, PKC-L is not down-regulated by phorbol ester treatment.","method":"Immunofluorescence staining, subcellular fractionation","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — two orthogonal localization methods (immunofluorescence + fractionation) in multiple cell lines, with functional implication (phorbol ester resistance), single lab","pmids":["1545811"],"is_preprint":false},{"year":2007,"finding":"PRKCH (PKCeta) is expressed mainly in vascular endothelial cells and foamy macrophages in human atherosclerotic lesions, with expression increasing as lesion type progresses, implicating PRKCH in endothelial/macrophage biology in vascular disease.","method":"Immunohistochemistry of human atherosclerotic tissue","journal":"Nature genetics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single localization method (IHC) in tissue sections, no functional manipulation","pmids":["17206144"],"is_preprint":false},{"year":2016,"finding":"PRKCH suppresses the p53/p21 pathway in lacrimal adenoid cystic carcinoma cells, promoting cell growth and migration/invasion, as demonstrated by PRKCH overexpression reducing p53 and p21 mRNA and protein levels, and rescue experiments showing ectopic PRKCH counteracts miR-24-3p-mediated tumor suppression.","method":"Overexpression and knockdown experiments, Western blot, mRNA quantification, rescue assays in ACC cells","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function and gain-of-function with defined molecular readout (p53/p21 pathway), single lab with multiple orthogonal methods","pmids":["27351203"],"is_preprint":false},{"year":2022,"finding":"miR-exon4 (derived from amelogenin exon4) directly targets the 3'-UTR of Prkch, leading to reduced PRKCH protein; in cells where miR-exon4 is inhibited, PRKCH is upregulated and mTOR kinase phosphorylation is enhanced, suggesting PRKCH acts upstream of mTOR to regulate Runx2 expression.","method":"Luciferase reporter assay (3'-UTR), Western blot, quantitative proteomics, pathway analysis in MC3T3-E1 osteoblast subclones","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct 3'-UTR interaction validated by reporter assay, mTOR phosphorylation confirmed by Western blot, single lab with multiple methods","pmids":["35271849"],"is_preprint":false},{"year":2020,"finding":"Huai Qi Huang (HQH) treatment down-regulates PRKCH mRNA and is associated with reduced CRAF, MEK4, phospho-ERK, and BCL2 proteins and increased cleaved caspase-3, promoting apoptosis in Ph+ leukemia cells; MEK4 knockdown synergizes with HQH, placing PRKCH upstream of the RAF/MEK/ERK pathway in these cells.","method":"Western blot, RT-qPCR, CCK-8 viability assay, flow cytometry (apoptosis), MEK4 knockdown/overexpression","journal":"Current medical science","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pathway placement inferred from expression changes after drug treatment rather than direct PRKCH manipulation; single lab, limited mechanistic rigor","pmids":["32337697"],"is_preprint":false},{"year":2025,"finding":"PARM1 knockdown down-regulates PRKCH mRNA expression, which attenuates MAPK pathway activation during osteogenic differentiation of valvular interstitial cells, placing PRKCH downstream of PARM1 and upstream of MAPK signaling in aortic valve calcification.","method":"PARM1 knockdown, mRNA and protein quantification, MAPK pathway analysis in valvular interstitial cells","journal":"JACC. Basic to translational science","confidence":"Low","confidence_rationale":"Tier 3 / Weak — PRKCH involvement inferred from its transcriptional down-regulation upon PARM1 knockdown; no direct PRKCH manipulation reported for PRKCH itself; single lab","pmids":["40439629"],"is_preprint":false},{"year":2025,"finding":"ROCK1 transcriptionally drives PRKCH expression via an ERK2-CREB1 signaling axis; CREB1 binds the PRKCH promoter (validated by luciferase reporter assay). PRKCH acts downstream of ROCK1 to regulate CRC cell motility and bioenergetic reprogramming (glycolytic flux and mitochondrial respiration); PRKCH overexpression partially restores migration and metabolism in ROCK1-deficient CRC cells.","method":"ROCK1/PRKCH knockdown and overexpression, transcriptomic profiling, luciferase reporter assay (PRKCH promoter), ERK2/CREB1 pharmacological/genetic inhibition, Seahorse metabolic assay, in vivo hepatic colonization assay","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods including promoter reporter assay, rescue experiments, and metabolic profiling; single lab","pmids":["41115563"],"is_preprint":false},{"year":2025,"finding":"A rare missense mutation K65R in PRKCH (in linkage disequilibrium with AD-associated variant rs7161410) leads to enhanced localization and signaling of PKCη at the Golgi apparatus, mechanistically linking aberrant Golgi-localized PKCη activity to Alzheimer's disease risk.","method":"Family-based GWAS (recessive model), whole genome sequencing, subcellular localization imaging, signaling assays in cells expressing K65R mutant","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetically validated variant with direct functional characterization (Golgi localization and signaling), single preprint lab report not yet peer-reviewed","pmids":["bio_10.1101_2025.05.13.25327562"],"is_preprint":true}],"current_model":"PRKCH (PKCη) is a novel diacylglycerol/phorbol ester-binding serine/threonine kinase with distinct substrate specificity compared to classical PKC isoforms; it localizes constitutively to the cell nucleus (and under certain mutation contexts to the Golgi), is resistant to phorbol ester-induced down-regulation, acts upstream of p53/p21 and MAPK/ERK pathways, and its transcription is regulated downstream of a ROCK1-ERK2-CREB1 axis, collectively implicating it in gene expression regulation, vascular biology, cancer cell motility, metabolic reprogramming, and Alzheimer's disease-associated Golgi signaling."},"narrative":{"mechanistic_narrative":"PRKCH (PKCη/PKC-L) is a phorbol ester- and diacylglycerol-responsive serine/threonine kinase that functions in gene expression control, cancer cell motility, and vascular and metabolic signaling [PMID:1986216, PMID:41115563]. Recombinant enzyme binds phorbol esters comparably to classical PKC isoforms but acts on conventional PKC substrates (histone, myelin basic protein, protamine) with distinct behavior, marking it as functionally divergent from group A PKC enzymes [PMID:1590767]. Unlike classical PKCs, PKCη localizes constitutively and specifically to the nucleus and is resistant to phorbol ester-induced down-regulation [PMID:1545811]. In cancer contexts, PRKCH suppresses the p53/p21 axis to promote growth and invasion and counteracts miR-24-3p-mediated tumor suppression [PMID:27351203], and it operates downstream of a ROCK1–ERK2–CREB1 transcriptional axis—with CREB1 binding the PRKCH promoter—to drive colorectal cancer cell migration and bioenergetic reprogramming of glycolysis and mitochondrial respiration [PMID:41115563]. Its transcript is regulated post-transcriptionally through 3'-UTR targeting, linking PRKCH to mTOR-dependent osteogenic signaling [PMID:35271849]. A rare K65R missense mutation enhances PKCη localization and signaling at the Golgi apparatus, connecting aberrant Golgi-localized activity to Alzheimer's disease risk [PMID:bio_10.1101_2025.05.13.25327562].","teleology":[{"year":1991,"claim":"Established that the PRKCH gene product is a functional phorbol ester-binding kinase, defining it as a PKC family enzyme.","evidence":"cDNA expression in COS cells with phorbol ester binding and kinase activity assays","pmids":["1986216"],"confidence":"Medium","gaps":["No physiological substrate identified","Activation mechanism beyond phorbol esters undefined"]},{"year":1992,"claim":"Reconstitution of recombinant enzyme showed PKCη binds phorbol esters like classical isoforms yet handles conventional PKC substrates differently, distinguishing it from group A PKCs and implying a unique substrate specificity.","evidence":"Baculovirus/insect-cell recombinant protein, phorbol ester binding and in vitro kinase assays with multiple substrates","pmids":["1590767"],"confidence":"High","gaps":["Bona fide endogenous substrates not identified","Whether incomplete activation vs. true specificity unresolved"]},{"year":1992,"claim":"Defined PKCη's unusual constitutive nuclear localization and resistance to phorbol ester down-regulation, setting it apart from classical PKCs and pointing to a role in nuclear/gene-expression functions.","evidence":"Immunofluorescence and subcellular fractionation across multiple human cell lines","pmids":["1545811"],"confidence":"High","gaps":["Nuclear targeting determinants unknown","Nuclear substrates not identified"]},{"year":2007,"claim":"Linked PRKCH expression to vascular disease, showing enrichment in endothelial cells and foamy macrophages of progressing atherosclerotic lesions.","evidence":"Immunohistochemistry of human atherosclerotic tissue","pmids":["17206144"],"confidence":"Low","gaps":["Single descriptive localization method without functional manipulation","Causal role in lesion progression untested"]},{"year":2016,"claim":"Placed PRKCH upstream of tumor-suppressive signaling by showing it suppresses the p53/p21 pathway to drive carcinoma growth and invasion.","evidence":"Overexpression/knockdown, Western blot, mRNA quantification, and miR-24-3p rescue assays in adenoid cystic carcinoma cells","pmids":["27351203"],"confidence":"Medium","gaps":["Direct vs. indirect mechanism of p53/p21 repression unclear","Kinase activity requirement not tested"]},{"year":2020,"claim":"Associated PRKCH with RAF/MEK/ERK survival signaling in leukemia cells, where its down-regulation accompanied reduced ERK activity and increased apoptosis.","evidence":"Drug (HQH) treatment with Western blot, RT-qPCR, viability/apoptosis assays, and MEK4 perturbation in Ph+ leukemia cells","pmids":["32337697"],"confidence":"Low","gaps":["Pathway placement inferred from expression changes, not direct PRKCH manipulation","Causal contribution of PRKCH to apoptosis unproven"]},{"year":2022,"claim":"Showed PRKCH is post-transcriptionally controlled via its 3'-UTR and acts upstream of mTOR, linking it to osteogenic gene regulation.","evidence":"Luciferase 3'-UTR reporter, Western blot, and proteomics in osteoblast subclones","pmids":["35271849"],"confidence":"Medium","gaps":["Mechanism by which PRKCH activates mTOR undefined","Direct kinase-substrate relationship not shown"]},{"year":2025,"claim":"Defined an upstream transcriptional circuit (ROCK1–ERK2–CREB1) driving PRKCH and connected PRKCH to cancer cell motility and metabolic reprogramming.","evidence":"ROCK1/PRKCH perturbation, PRKCH-promoter luciferase reporter, ERK2/CREB1 inhibition, Seahorse assays, and in vivo colonization in CRC cells","pmids":["41115563"],"confidence":"Medium","gaps":["PRKCH kinase substrates mediating metabolic effects unknown","Direct CREB1 promoter occupancy in vivo not shown"]},{"year":2025,"claim":"Connected a PRKCH coding variant to disease by showing the K65R mutation enhances Golgi localization and signaling of PKCη, implicating aberrant Golgi-localized activity in Alzheimer's disease risk.","evidence":"Family-based GWAS, whole genome sequencing, and localization/signaling assays for the K65R mutant (preprint)","pmids":["bio_10.1101_2025.05.13.25327562"],"confidence":"Medium","gaps":["Not yet peer-reviewed","Mechanism by which K65R redirects localization to Golgi unresolved","Downstream AD-relevant substrates undefined"]},{"year":null,"claim":"The physiological substrates and the molecular basis of PKCη's distinct substrate specificity and compartment-specific (nuclear vs. Golgi) signaling remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No direct endogenous kinase substrate identified","Structural basis of substrate selectivity unknown","Determinants of nuclear vs. Golgi targeting uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[0,1]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[9]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[6,8]}],"complexes":[],"partners":[],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"C0HM02","full_name":"PRKCH upstream open reading frame 2","aliases":["Protein uPEP2"],"length_aa":26,"mass_kda":2.8,"function":"Product of an upstream open reading frame (ORF) of PRKCH which regulates translation of the downstream protein kinase C eta (PKC-eta) ORF (PubMed:19797084, PubMed:34593629). Functions as a repressive element that maintains low basal levels of PKC-eta in growing cells but enhances its expression during stress conditions induced by amino acid starvation in a EIF2AK4/GCN2-dependent manner (PubMed:19797084, PubMed:34593629). In addition to its role in regulating PKC-eta translation, also inhibits the kinase activity of PKC-eta as well as other protein kinases including PRKCD, PRKCQ and PRKCE but not PRKCA, PRKCG or PRKCZ (PubMed:34593629)","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/C0HM02/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PRKCH","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PRKCH","total_profiled":1310},"omim":[{"mim_id":"616450","title":"EF-HAND DOMAIN FAMILY, MEMBER D2; EFHD2","url":"https://www.omim.org/entry/616450"},{"mim_id":"610924","title":"RANBP-TYPE AND C3HC4-TYPE ZINC FINGER-CONTAINING 1; RBCK1","url":"https://www.omim.org/entry/610924"},{"mim_id":"605437","title":"PROTEIN KINASE C, ETA; PRKCH","url":"https://www.omim.org/entry/605437"},{"mim_id":"601367","title":"STROKE, ISCHEMIC","url":"https://www.omim.org/entry/601367"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PRKCH"},"hgnc":{"alias_symbol":["PKC-L","PKCL"],"prev_symbol":["PRKCL"]},"alphafold":{"accession":"C0HM02","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/C0HM02","model_url":"https://alphafold.ebi.ac.uk/files/AF-C0HM02-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-C0HM02-F1-predicted_aligned_error_v6.png","plddt_mean":67.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PRKCH","jax_strain_url":"https://www.jax.org/strain/search?query=PRKCH"},"sequence":{"accession":"C0HM02","fasta_url":"https://rest.uniprot.org/uniprotkb/C0HM02.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/C0HM02/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/C0HM02"}},"corpus_meta":[{"pmid":"1986216","id":"PMC_1986216","title":"Isolation and characterization of PKC-L, a new member of the protein kinase C-related gene family specifically expressed in lung, skin, and heart.","date":"1991","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1986216","citation_count":212,"is_preprint":false},{"pmid":"17206144","id":"PMC_17206144","title":"A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of cerebral infarction.","date":"2007","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17206144","citation_count":165,"is_preprint":false},{"pmid":"1590767","id":"PMC_1590767","title":"Protein kinase C group B members PKC-delta, -epsilon, -zeta and PKC-L(eta). Comparison of properties of recombinant proteins in vitro and in vivo.","date":"1992","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/1590767","citation_count":132,"is_preprint":false},{"pmid":"1545811","id":"PMC_1545811","title":"The protein kinase C-related PKC-L(eta) gene product is localized in the cell nucleus.","date":"1992","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1545811","citation_count":80,"is_preprint":false},{"pmid":"19520989","id":"PMC_19520989","title":"The 1425G/A SNP in PRKCH is associated with ischemic stroke and cerebral hemorrhage in a Chinese population.","date":"2009","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/19520989","citation_count":49,"is_preprint":false},{"pmid":"18164711","id":"PMC_18164711","title":"Association between PRKCH gene polymorphisms and subcortical silent brain infarction.","date":"2007","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/18164711","citation_count":36,"is_preprint":false},{"pmid":"17195206","id":"PMC_17195206","title":"Genetic association between the PRKCH gene encoding protein kinase Ceta isozyme and rheumatoid arthritis in the Japanese population.","date":"2007","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/17195206","citation_count":33,"is_preprint":false},{"pmid":"27351203","id":"PMC_27351203","title":"miR-24-3p Suppresses Malignant Behavior of Lacrimal Adenoid Cystic Carcinoma by Targeting PRKCH to Regulate p53/p21 Pathway.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27351203","citation_count":22,"is_preprint":false},{"pmid":"21756056","id":"PMC_21756056","title":"Contribution of 1425G/A polymorphism in protein kinase C-Eta (PRKCH) gene and brain white matter lesions to the risk of sudden sensorineural hearing loss in a Japanese nested case-control study.","date":"2011","source":"Journal of neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/21756056","citation_count":17,"is_preprint":false},{"pmid":"22044875","id":"PMC_22044875","title":"Association between 1425G/A SNP in PRKCH and ischemic stroke among Chinese and Japanese populations: a meta-analysis including 3686 cases and 4589 controls.","date":"2011","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/22044875","citation_count":13,"is_preprint":false},{"pmid":"20602195","id":"PMC_20602195","title":"PRKCH gene polymorphism is associated with the risk of severe gastric atrophy.","date":"2010","source":"Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association","url":"https://pubmed.ncbi.nlm.nih.gov/20602195","citation_count":13,"is_preprint":false},{"pmid":"19703523","id":"PMC_19703523","title":"Association of PRKCH gene with lacunar infarction in a local Chinese Han population.","date":"2009","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/19703523","citation_count":11,"is_preprint":false},{"pmid":"35352613","id":"PMC_35352613","title":"Knockdown of circ-PRKCH alleviates IL-1β-treated chondrocyte cell phenotypic changes through modulating miR-502-5p/ADAMTS5 axis.","date":"2022","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/35352613","citation_count":8,"is_preprint":false},{"pmid":"33880996","id":"PMC_33880996","title":"Silencing of circ-PRKCH protects against lipopolysaccharide (LPS)-evoked chondrocyte damage and extracellular matrix loss by the miR-140-3p/ADAM10 axis.","date":"2021","source":"General physiology and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/33880996","citation_count":8,"is_preprint":false},{"pmid":"21479425","id":"PMC_21479425","title":"Association of the genetic variants of APOA5 and PRKCH with hypertension in community-dwelling Japanese individuals.","date":"2008","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/21479425","citation_count":7,"is_preprint":false},{"pmid":"17957454","id":"PMC_17957454","title":"Association and expression study of PRKCH gene in a French Caucasian population with rheumatoid arthritis.","date":"2007","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17957454","citation_count":6,"is_preprint":false},{"pmid":"35271849","id":"PMC_35271849","title":"An miRNA derived from amelogenin exon4 regulates expression of transcription factor Runx2 by directly targeting upstream activators Nfia and Prkch.","date":"2022","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35271849","citation_count":6,"is_preprint":false},{"pmid":"29383124","id":"PMC_29383124","title":"Genetic association between 1425G/A SNP in PRKCH and hypertrophic cardiomyopathy in a Chinese population.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29383124","citation_count":6,"is_preprint":false},{"pmid":"36434855","id":"PMC_36434855","title":"Overexpression of PRKCH promotes tumorigenesis in patients with glioma and influences glioma stem cell properties.","date":"2022","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/36434855","citation_count":5,"is_preprint":false},{"pmid":"36377982","id":"PMC_36377982","title":"Mechanisms of PALLD, PRKCH, AKAP12, PDK4, and CHIT1 Proteins in Serum Diagnosis of Neonatal Sepsis.","date":"2022","source":"Clinical laboratory","url":"https://pubmed.ncbi.nlm.nih.gov/36377982","citation_count":5,"is_preprint":false},{"pmid":"21625852","id":"PMC_21625852","title":"The role of PRKCH gene variants in coronary artery disease in a Chinese population.","date":"2011","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21625852","citation_count":4,"is_preprint":false},{"pmid":"32337697","id":"PMC_32337697","title":"Huai Qi Huang-induced Apoptosis via Down-regulating PRKCH and Inhibiting RAF/MEK/ERK Pathway in Ph+ Leukemia Cells.","date":"2020","source":"Current medical science","url":"https://pubmed.ncbi.nlm.nih.gov/32337697","citation_count":3,"is_preprint":false},{"pmid":"32985204","id":"PMC_32985204","title":"MicroRNA-185 reduces the expression of hepatitis B virus surface antigen by targeting PRKCH in HepG2 2.2.15 cells.","date":"2020","source":"Acta virologica","url":"https://pubmed.ncbi.nlm.nih.gov/32985204","citation_count":3,"is_preprint":false},{"pmid":"22808203","id":"PMC_22808203","title":"The SNP (rs2230500) in PRKCH decreases the risk of carotid intima-media thickness in a Chinese young adult population.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22808203","citation_count":3,"is_preprint":false},{"pmid":"28640647","id":"PMC_28640647","title":"Influence of PRKCH gene polymorphism on antihypertensive response to amlodipine and telmisartan.","date":"2017","source":"Clinical and experimental hypertension (New York, N.Y. : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/28640647","citation_count":2,"is_preprint":false},{"pmid":"24534126","id":"PMC_24534126","title":"Impact of the 1425G/A polymorphism of PRKCH on the recurrence of ischemic stroke: Fukuoka Stroke Registry.","date":"2014","source":"Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association","url":"https://pubmed.ncbi.nlm.nih.gov/24534126","citation_count":2,"is_preprint":false},{"pmid":"36615902","id":"PMC_36615902","title":"Perinatal Fat-Diets Increased Angiotensin II-Mediated Ca2+ through PKC-L-Type Calcium Channel Axis in Resistance Arteries via Agtr1a-Prkcb Gene Methylation.","date":"2023","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/36615902","citation_count":2,"is_preprint":false},{"pmid":"40439629","id":"PMC_40439629","title":"Knockdown of PARM1 Alleviates Aortic Valve Calcification via the PRKCH-MAPK Signaling Pathway.","date":"2025","source":"JACC. Basic to translational science","url":"https://pubmed.ncbi.nlm.nih.gov/40439629","citation_count":0,"is_preprint":false},{"pmid":"41115563","id":"PMC_41115563","title":"ROCK1 drives colorectal cancer liver metastasis via PRKCH-mediated bioenergetic reprogramming.","date":"2025","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/41115563","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.05.13.25327562","title":"Protein kinase C eta enhances Golgi-localized signaling and is associated with Alzheimer’s disease using a recessive mode of inheritance","date":"2025-05-14","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.13.25327562","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":16802,"output_tokens":2497,"usd":0.04393,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9676,"output_tokens":2933,"usd":0.060852,"stage2_stop_reason":"end_turn"},"total_usd":0.104782,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1991,\n      \"finding\": \"PKC-L (PRKCH) binds phorbol esters and has kinase activity stimulated by phorbol esters, as demonstrated by introduction of the cDNA into COS cells.\",\n      \"method\": \"COS cell expression, phorbol ester binding assay, kinase activity assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct kinase activity and phorbol ester binding demonstrated in COS cells, single lab, two orthogonal methods (binding + kinase assay)\",\n      \"pmids\": [\"1986216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Recombinant PKC-L(eta) expressed in insect cells via baculovirus binds phorbol ester similarly to PKC-gamma but shows distinctively different behavior toward conventional PKC substrates (histone, myelin basic protein, protamine), suggesting either incomplete activation by phorbol esters or different substrate specificity compared to group A PKC enzymes.\",\n      \"method\": \"Baculovirus/insect cell recombinant protein expression, phorbol ester binding assay, in vitro kinase assay with multiple substrates\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic reconstitution with multiple substrates and orthogonal binding assay, single lab\",\n      \"pmids\": [\"1590767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"PKC-L (PRKCH) is localized permanently and specifically in the cell nucleus, as shown by immunofluorescence staining and subcellular fractionation of multiple human cell lines including A431. Unlike classical PKC members, PKC-L is not down-regulated by phorbol ester treatment.\",\n      \"method\": \"Immunofluorescence staining, subcellular fractionation\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal localization methods (immunofluorescence + fractionation) in multiple cell lines, with functional implication (phorbol ester resistance), single lab\",\n      \"pmids\": [\"1545811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PRKCH (PKCeta) is expressed mainly in vascular endothelial cells and foamy macrophages in human atherosclerotic lesions, with expression increasing as lesion type progresses, implicating PRKCH in endothelial/macrophage biology in vascular disease.\",\n      \"method\": \"Immunohistochemistry of human atherosclerotic tissue\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single localization method (IHC) in tissue sections, no functional manipulation\",\n      \"pmids\": [\"17206144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PRKCH suppresses the p53/p21 pathway in lacrimal adenoid cystic carcinoma cells, promoting cell growth and migration/invasion, as demonstrated by PRKCH overexpression reducing p53 and p21 mRNA and protein levels, and rescue experiments showing ectopic PRKCH counteracts miR-24-3p-mediated tumor suppression.\",\n      \"method\": \"Overexpression and knockdown experiments, Western blot, mRNA quantification, rescue assays in ACC cells\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function and gain-of-function with defined molecular readout (p53/p21 pathway), single lab with multiple orthogonal methods\",\n      \"pmids\": [\"27351203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"miR-exon4 (derived from amelogenin exon4) directly targets the 3'-UTR of Prkch, leading to reduced PRKCH protein; in cells where miR-exon4 is inhibited, PRKCH is upregulated and mTOR kinase phosphorylation is enhanced, suggesting PRKCH acts upstream of mTOR to regulate Runx2 expression.\",\n      \"method\": \"Luciferase reporter assay (3'-UTR), Western blot, quantitative proteomics, pathway analysis in MC3T3-E1 osteoblast subclones\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct 3'-UTR interaction validated by reporter assay, mTOR phosphorylation confirmed by Western blot, single lab with multiple methods\",\n      \"pmids\": [\"35271849\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Huai Qi Huang (HQH) treatment down-regulates PRKCH mRNA and is associated with reduced CRAF, MEK4, phospho-ERK, and BCL2 proteins and increased cleaved caspase-3, promoting apoptosis in Ph+ leukemia cells; MEK4 knockdown synergizes with HQH, placing PRKCH upstream of the RAF/MEK/ERK pathway in these cells.\",\n      \"method\": \"Western blot, RT-qPCR, CCK-8 viability assay, flow cytometry (apoptosis), MEK4 knockdown/overexpression\",\n      \"journal\": \"Current medical science\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pathway placement inferred from expression changes after drug treatment rather than direct PRKCH manipulation; single lab, limited mechanistic rigor\",\n      \"pmids\": [\"32337697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PARM1 knockdown down-regulates PRKCH mRNA expression, which attenuates MAPK pathway activation during osteogenic differentiation of valvular interstitial cells, placing PRKCH downstream of PARM1 and upstream of MAPK signaling in aortic valve calcification.\",\n      \"method\": \"PARM1 knockdown, mRNA and protein quantification, MAPK pathway analysis in valvular interstitial cells\",\n      \"journal\": \"JACC. Basic to translational science\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — PRKCH involvement inferred from its transcriptional down-regulation upon PARM1 knockdown; no direct PRKCH manipulation reported for PRKCH itself; single lab\",\n      \"pmids\": [\"40439629\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ROCK1 transcriptionally drives PRKCH expression via an ERK2-CREB1 signaling axis; CREB1 binds the PRKCH promoter (validated by luciferase reporter assay). PRKCH acts downstream of ROCK1 to regulate CRC cell motility and bioenergetic reprogramming (glycolytic flux and mitochondrial respiration); PRKCH overexpression partially restores migration and metabolism in ROCK1-deficient CRC cells.\",\n      \"method\": \"ROCK1/PRKCH knockdown and overexpression, transcriptomic profiling, luciferase reporter assay (PRKCH promoter), ERK2/CREB1 pharmacological/genetic inhibition, Seahorse metabolic assay, in vivo hepatic colonization assay\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods including promoter reporter assay, rescue experiments, and metabolic profiling; single lab\",\n      \"pmids\": [\"41115563\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"A rare missense mutation K65R in PRKCH (in linkage disequilibrium with AD-associated variant rs7161410) leads to enhanced localization and signaling of PKCη at the Golgi apparatus, mechanistically linking aberrant Golgi-localized PKCη activity to Alzheimer's disease risk.\",\n      \"method\": \"Family-based GWAS (recessive model), whole genome sequencing, subcellular localization imaging, signaling assays in cells expressing K65R mutant\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetically validated variant with direct functional characterization (Golgi localization and signaling), single preprint lab report not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.05.13.25327562\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"PRKCH (PKCη) is a novel diacylglycerol/phorbol ester-binding serine/threonine kinase with distinct substrate specificity compared to classical PKC isoforms; it localizes constitutively to the cell nucleus (and under certain mutation contexts to the Golgi), is resistant to phorbol ester-induced down-regulation, acts upstream of p53/p21 and MAPK/ERK pathways, and its transcription is regulated downstream of a ROCK1-ERK2-CREB1 axis, collectively implicating it in gene expression regulation, vascular biology, cancer cell motility, metabolic reprogramming, and Alzheimer's disease-associated Golgi signaling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PRKCH (PKCη/PKC-L) is a phorbol ester- and diacylglycerol-responsive serine/threonine kinase that functions in gene expression control, cancer cell motility, and vascular and metabolic signaling [#0, #8]. Recombinant enzyme binds phorbol esters comparably to classical PKC isoforms but acts on conventional PKC substrates (histone, myelin basic protein, protamine) with distinct behavior, marking it as functionally divergent from group A PKC enzymes [#1]. Unlike classical PKCs, PKCη localizes constitutively and specifically to the nucleus and is resistant to phorbol ester-induced down-regulation [#2]. In cancer contexts, PRKCH suppresses the p53/p21 axis to promote growth and invasion and counteracts miR-24-3p-mediated tumor suppression [#4], and it operates downstream of a ROCK1–ERK2–CREB1 transcriptional axis—with CREB1 binding the PRKCH promoter—to drive colorectal cancer cell migration and bioenergetic reprogramming of glycolysis and mitochondrial respiration [#8]. Its transcript is regulated post-transcriptionally through 3'-UTR targeting, linking PRKCH to mTOR-dependent osteogenic signaling [#5]. A rare K65R missense mutation enhances PKCη localization and signaling at the Golgi apparatus, connecting aberrant Golgi-localized activity to Alzheimer's disease risk [#9].\",\n  \"teleology\": [\n    {\n      \"year\": 1991,\n      \"claim\": \"Established that the PRKCH gene product is a functional phorbol ester-binding kinase, defining it as a PKC family enzyme.\",\n      \"evidence\": \"cDNA expression in COS cells with phorbol ester binding and kinase activity assays\",\n      \"pmids\": [\"1986216\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No physiological substrate identified\", \"Activation mechanism beyond phorbol esters undefined\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Reconstitution of recombinant enzyme showed PKCη binds phorbol esters like classical isoforms yet handles conventional PKC substrates differently, distinguishing it from group A PKCs and implying a unique substrate specificity.\",\n      \"evidence\": \"Baculovirus/insect-cell recombinant protein, phorbol ester binding and in vitro kinase assays with multiple substrates\",\n      \"pmids\": [\"1590767\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Bona fide endogenous substrates not identified\", \"Whether incomplete activation vs. true specificity unresolved\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Defined PKCη's unusual constitutive nuclear localization and resistance to phorbol ester down-regulation, setting it apart from classical PKCs and pointing to a role in nuclear/gene-expression functions.\",\n      \"evidence\": \"Immunofluorescence and subcellular fractionation across multiple human cell lines\",\n      \"pmids\": [\"1545811\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Nuclear targeting determinants unknown\", \"Nuclear substrates not identified\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Linked PRKCH expression to vascular disease, showing enrichment in endothelial cells and foamy macrophages of progressing atherosclerotic lesions.\",\n      \"evidence\": \"Immunohistochemistry of human atherosclerotic tissue\",\n      \"pmids\": [\"17206144\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single descriptive localization method without functional manipulation\", \"Causal role in lesion progression untested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Placed PRKCH upstream of tumor-suppressive signaling by showing it suppresses the p53/p21 pathway to drive carcinoma growth and invasion.\",\n      \"evidence\": \"Overexpression/knockdown, Western blot, mRNA quantification, and miR-24-3p rescue assays in adenoid cystic carcinoma cells\",\n      \"pmids\": [\"27351203\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs. indirect mechanism of p53/p21 repression unclear\", \"Kinase activity requirement not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Associated PRKCH with RAF/MEK/ERK survival signaling in leukemia cells, where its down-regulation accompanied reduced ERK activity and increased apoptosis.\",\n      \"evidence\": \"Drug (HQH) treatment with Western blot, RT-qPCR, viability/apoptosis assays, and MEK4 perturbation in Ph+ leukemia cells\",\n      \"pmids\": [\"32337697\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Pathway placement inferred from expression changes, not direct PRKCH manipulation\", \"Causal contribution of PRKCH to apoptosis unproven\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed PRKCH is post-transcriptionally controlled via its 3'-UTR and acts upstream of mTOR, linking it to osteogenic gene regulation.\",\n      \"evidence\": \"Luciferase 3'-UTR reporter, Western blot, and proteomics in osteoblast subclones\",\n      \"pmids\": [\"35271849\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which PRKCH activates mTOR undefined\", \"Direct kinase-substrate relationship not shown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defined an upstream transcriptional circuit (ROCK1–ERK2–CREB1) driving PRKCH and connected PRKCH to cancer cell motility and metabolic reprogramming.\",\n      \"evidence\": \"ROCK1/PRKCH perturbation, PRKCH-promoter luciferase reporter, ERK2/CREB1 inhibition, Seahorse assays, and in vivo colonization in CRC cells\",\n      \"pmids\": [\"41115563\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"PRKCH kinase substrates mediating metabolic effects unknown\", \"Direct CREB1 promoter occupancy in vivo not shown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Connected a PRKCH coding variant to disease by showing the K65R mutation enhances Golgi localization and signaling of PKCη, implicating aberrant Golgi-localized activity in Alzheimer's disease risk.\",\n      \"evidence\": \"Family-based GWAS, whole genome sequencing, and localization/signaling assays for the K65R mutant (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.05.13.25327562\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Not yet peer-reviewed\", \"Mechanism by which K65R redirects localization to Golgi unresolved\", \"Downstream AD-relevant substrates undefined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The physiological substrates and the molecular basis of PKCη's distinct substrate specificity and compartment-specific (nuclear vs. Golgi) signaling remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct endogenous kinase substrate identified\", \"Structural basis of substrate selectivity unknown\", \"Determinants of nuclear vs. Golgi targeting uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}